Methods of treating pruritis (e.g., associated with atopic dermatitis or psoriasis) are described. The methods can involve administering to a subject in need of treatment an antagonist of integrin α.sub.vβ.sub.3. The antagonist can block periostin-integrin signalling. The antagonist can be, for example, an antibody, a peptide having a RGD or SVD sequence, a peptidomimetic, an amine salt, a phosphoric acid salt, or a small molecule.

The present invention relates to compositions, methods, uses and kits for the treatment of renal cystogenesis. In particular, the compositions, methods, uses and kits are particularly useful, but not limited to, the treatment or prevention of Polycystic Kidney Disease. In one aspect, the prevent invention provides a method of minimising or delaying renal cystogenesis in a subject in need thereof, the method comprising inhibiting AKT in the subject, or reducing the level of Aurora kinase in the subject, thereby minimising or delaying renal cystogenesis.

Provided herein are compositions comprising niacin, berberine, one or more of silymarin, silibinin, and Siliphos®, lipoic acid, taurine, and phosphatidylcholine. Such compositions are useful for treating or preventing obesity, metabolic and hepatic and neurodegenerative disorders.

Provided herein are compositions comprising niacin, berberine, one or more of silymarin, silibinin, and Siliphos®, lipoic acid, taurine, and phosphatidylcholine. Such compositions are useful for treating or preventing obesity, metabolic and hepatic and neurodegenerative disorders.

Provided herein are compositions comprising niacin, berberine, one or more of silymarin, silibinin, and Siliphos®, lipoic acid, taurine, and phosphatidylcholine. Such compositions are useful for treating or preventing obesity, metabolic and hepatic and neurodegenerative disorders.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

This invention discloses a nutritional composition of matter that effectively provide a nootropic effect beyond the effects simple obtain by cannabinoids alone. Effectively reduce anxiety due to ingestion of xanthines containing oral products. Similarly reduce the side effects associated with the exogenous ingestion of yohimbine and its derivatives.

This invention discloses a nutritional composition of matter that effectively provide a nootropic effect beyond the effects simple obtain by cannabinoids alone. Effectively reduce anxiety due to ingestion of xanthines containing oral products. Similarly reduce the side effects associated with the exogenous ingestion of yohimbine and its derivatives.

The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).